Stimulus-Responsive Nanodelivery and Release Systems for Cancer Gene Therapy: Efficacy Improvement Strategies
Huamin Zeng,Yiran Zhang,Ningyi Liu,Qingqing Wei,Fan Yang,Jie Li
DOI: https://doi.org/10.2147/ijn.s470637
IF: 7.033
2024-07-13
International Journal of Nanomedicine
Abstract:Huamin Zeng, 1 Yiran Zhang, 1, 2 Ningyi Liu, 1, 3 Qingqing Wei, 1, 3 Fan Yang, 1 Jie Li 4 1 Cancer Prevention and Treatment Institute of Chengdu, Department of Pathology, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, Sichuan, 611130, People's Republic of China; 2 School of Medical and Life Sciences, Chengdu University of traditional Chinese Medicine, Chengdu, Sichuan, 611137, People's Republic of China; 3 School of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, 637007, People's Republic of China; 4 Institute of Herbgenomics, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People's Republic of China Correspondence: Jie Li, Institute of Herbgenomics, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People's Republic of China, Tel +86 183 0831 2997, Email Fan Yang, Cancer Prevention and Treatment Institute of Chengdu, Department of Pathology, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, Sichuan, 611130, People's Republic of China, Tel +86 136 7819 2175, Email Introduction of exogenous genes into target cells to overcome various tumor diseases caused by genetic defects or abnormalities and gene therapy, a new treatment method, provides a promising strategy for tumor treatment. Over the past decade, gene therapy has made exciting progress; however, it still faces the challenge of low nucleic acid delivery and release efficiencies. The emergence of nonviral vectors, primarily nanodelivery and release systems (NDRS), has resulted in a historic breakthrough in the application of gene therapy. NDRS, especially stimulus-responsive NDRS that can respond in a timely manner to changes in the internal and external microenvironment (eg, low pH, high concentration of glutathione/reactive oxygen species, overexpressed enzymes, temperature, light, ultrasound, and magnetic field), has shown excellent loading and release advantages in the precision and efficiency of tumor gene therapy and has been widely applied. The only disadvantage is that poor transfection efficiency limits the in-depth application of gene therapy in clinical practice, owing to the presence of biological barriers in the body. Therefore, this review first introduces the development history of gene therapy, the current obstacles faced by gene delivery, strategies to overcome these obstacles, and conventional vectors, and then focuses on the latest research progress in various stimulus-responsive NDRS for improving gene delivery efficiency. Finally, the future challenges and prospects that stimulus-responsive NDRS may face in clinical application and transformation are discussed to provide references for enhancing in-depth research on tumor gene therapy. Keywords: stimulus-responsive NDRS, gene delivery, tumor treatment, delivery and release efficiency, tumor microenvironment, physiological barrier, efficacy improvement strategies Despite improvements in cancer treatment over the past few decades, malignant tumors remain the leading cause of patient deaths. Breakthroughs in diagnostic and therapeutic technologies are crucial for steering humanity away from cancer and achieving good health. Currently, the main treatment strategy for tumors still revolves around chemotherapy, which yields noticeable treatment effects but also brings about significant toxic side effects, poor selectivity, high tumor recurrence rates, and drug resistance, causing unbearable suffering for patients. Therefore, an effective and low-toxicity strategy is of immense significance for cancer treatment. Tumors typically originate from abnormal gene expressions or mutations. Gene therapy aims to introduce exogenous genes into target cells, altering or modifying defective and/or missing gene sequences to cure acquired or genetic diseases. 1 Therefore, by treating at the genetic level, it is theoretically possible to correct abnormal genes in tumor cells, achieving the goal of treating the source of the disease. Nucleic acid molecules used for cancer gene therapy mainly include plasmid DNA (pDNA), short hairpin RNA (shRNA), microRNA (miRNA), messenger RNA (mRNA), small interfering RNA (siRNA), immunostimulatory CpG oligodeoxynucleotides, enzymes, and gene editing systems (such as the CRISPR/Cas9 system). 2,3 In 2018, the US Food and Drug Administration (FDA) approved the first siRNA drug, Patisiran (ONPATTRO), for the treatment of hereditary transthyretin-mediated amyloidosis with multiple peripheral neuropathy.<s -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology